Last updated on August 2020

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.


Brief description of study

The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF.

The secondary objectives are to investigate the effect of BI 1015550 on the target engagement biomarker and to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.

Clinical Study Identifier: NCT03422068

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.